for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Allakos Inc

ALLK.OQ

Latest Trade

69.97USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

30.50

 - 

92.82

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
69.97
Open
--
Volume
--
3M AVG Volume
14.59
Today's High
--
Today's Low
--
52 Week High
92.82
52 Week Low
30.50
Shares Out (MIL)
48.41
Market Cap (MIL)
3,230.51
Forward P/E
-38.24
Dividend (Yield %)
--

Next Event

Allakos Inc Annual Shareholders Meeting

Latest Developments

More

Allakos Inc Files For Potential Stock Shelf, Size Not Disclosed

Allakos Inc Files For Offering $200 Million Of Shares Of Common Stock

Allakos Announces Proposed Public Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Allakos Inc

Allakos, Inc. is a clinical-stage biotechnology company, which is engaged in developing antibodies that selectively target mast cells and eosinophils. The Company's antibodies target receptor molecules present on the surface of immune effector cells, which are involved in allergy, inflammation and tissue damage. Its lead program is AK002, which is an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. The Company's AK002 is used in the treatment of various diseases with abnormal proliferation of mast cells, including eosinophilic gastritis (EG), indolent systemic mastocytosis, urticaria and allergic conjunctivitis.

Industry

Biotechnology & Drugs

Contact Info

975 Island Dr Ste 201

+1.650.5975002

http://www.allakos.com/

Executive Leadership

Daniel S. Janney

Independent Chair of the Board

Adam Tomasi

President, Chief Operating Officer

Robert D. Alexander

Chief Executive Officer, Director

Leo Redmond

Chief Financial Officer

Sally D. Bolmer

Vice President - Regulatory Affairs and Drug Development

Key Stats

1.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019(E)

0.0K
EPS (USD)

2018

-2.200

2019(E)

-1.745
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
18.94
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-56.34
Return on Equity (TTM)
-53.03

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up